References

  • 1. IMS Data 2012.
  • 2. Pharmacy Today (2011) Pharmacists’ Pick of the Top OTCs, #1 pharmacist recommended OTC.
  • 3. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH (1993) Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10: 1615-1619.
  • 4. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20: 192-196.
  • 5. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y (2008) Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology: 135(2): 568-579.
  • 6. Schneider SM, Girard-Pipau F, Filippi J, Hebuterne X, Moyse D, et al. (2005) Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11: 6165-6169.
  • 7. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, et al. (2009) Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 191: 623-630.
  • 8. Vandenplas Y, Brunser O, Szajewska H (2009) Saccharomyces boulardii in childhood. Eur J Pediatr 168: 253-265.
  • 9. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (2008) Guidelines for the Evaluation of Probiotics in Food. London Ontario, Canada: FAO/WHO.
  • 10. Blehaut H et al., Biopharmaceutics and Drug Disposition, 1989; 10:353-364.